Bempegaldesleukin Plus Nivolumab in First-Line Metastatic MelanomaAdi Diab, Michael E. Hurwitz, Sekwon Jang et al.|Journal of Clinical Oncology|2021Cited by 81
Baseline tumor-immune signatures associated with response to bempegaldesleukin (NKTR-214) and nivolumab.Michael E. Hurwitz, Adi Diab, Daniel C. Cho et al.|Journal of Clinical Oncology|2019Cited by 22
420 Progression-free survival and biomarker correlates of response with BEMPEG plus NIVO in previously untreated patients with metastatic melanoma: results from the PIVOT-02 studyAdi Diab, Michael E. Hurwitz, Scott S. Tykodi et al.|Regular and Young Investigator Award Abstracts|2020Cited by 7